The HEROS study is an Italian observational multicenter prospective study aimed to investigate the current diagnostic and therapeutical approach towards HER2 mutated NSCLC in clinical practice. The enrolment will start in September 2024 until September 2025. A 12-months follow-up window will be performed.
Male or female, aged at least 18 years.
Pathologically confirmed diagnosis of NSCLC from September 2024 to September 2025.
Locally advanced (IIIC), not amenable to multimodal approach (chemo-radiotherapy), or metastatic (IV) NSCLC according to TNM VIII edition.
Enrolled in ATLAS project. Cohort 2 (HER2 mutations study population)
None
Patients with HER2-mutated advanced non-small cell lung cancer
Cohort
Prospective
Not listed
Prevalence of HER2 mutation
Percentage of advanced NSCLC with HER2 mutations in Italy clinical practice.
Click on the lead sponsor to view all of their trials.
Gruppo Oncologico Italiano di Ricerca Clinica
Lead sponsor
AstraZeneca
Collaborator
